Erythropoietin And/Or Iron Sucrose For Perioperative Anemia Management In Hip and Knee Arthroplasty

Chinese Academy of Medical Sciences & Peking Union Medical College

Status: Unknown

Conditions: Anemia, Iron Deficiency

Treatments: Drug: Iron sucrose; Drug: rHuEPO

Study type: Observational

Funder types: Other

Identifiers

NCT03917394

EPO-retro-cohort-PUMCH

Details and patient eligibility

About

Perioperative anemia is very common in patients undergoing total hip arthroplasty (THA) and total knee arthroplasty (TKA). This study retrospectively analyzes the use of rHuEPO and iron sucrose in patients undergoing total hip and knee arthroplasty in order to observe the short-term efficacy and safety of rHuEPO and iron sucrose.

Full description

This study aims to explore whether short-term use of rHuEPO and iron sucrose can improve postoperative anemia and promote postoperative rehabilitation after hip and knee arthroplasty. According to different therapies of perioperative anemia , included subjects would be divided into rHuEPO monotherapy group, iron sucrose monotherapy group, rHuEPO combined with iron sucrose group and control group (without rHuEPO and iron sucrose).

Enrollment: 780 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Patients who underwent hip or knee arthroplasty between May 1, 2012 (included) and December 31, 2015 in Peking Union Medical College Hospital
2. Age ≥ 18 years, sex unlimited

Exclusion criteria

1. Patients with serious absence of clinical data

2. Patients with rHuEPO contraindication

   1. Patients with uncontrolled severe hypertension
   2. Patients allergic to this product and other mammalian cell derivatives, or to human serum albumin
   3. Co-infected patients

3. Patients definitely allergic to iron sucrose injection

4. Patients with coagulation dysfunction

Trial design

780 participants in 4 patient groups

rHuEPO monotherapy group

Description:

rHuEPO was administrated during hospitalization period.

Treatment:

Drug: rHuEPO

iron sucrose monotherapy group

Description:

Iron sucrose was administrated during hospitalization period.

Treatment:

Drug: Iron sucrose

rHuEPO combined with iron sucrose group

Description:

rHuEPO combined with iron sucrose was administrated during hospitalization period.

Treatment:

Drug: rHuEPO

Drug: Iron sucrose

control group

Description:

Subjects didn't be administrated with rHuEPO and/or iron sucrose during hospitalization period.